3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastric Cancer After D2 Lymph Node Dissection
1
Gallbladder Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Interventions
Everolimus
17
lutetium Lu 177 dotatate
7
Octreotide
7
pasireotide
6
lanreotide
6
gallium Ga 68 dotatate
5
Temozolomide
5
Sunitinib
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
pembrolizumab
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroendocrine Tumors
×
Somatostatin
×
Clear all
NCT04129255
2020-09-10
CSMS99
National Cancer Institute, Naples
Phase 2
Completed
34 enrolled